News

Novartis enters into licensing agreement with Ionis

The Basel-based pharmaceutical group Novartis is expanding its cardiovascular portfolio by entering into an exclusive option agreement with the US company Ionis and its affiliate Akcea to license two novel treatments.

The Basel-based pharmaceutical group Novartis enters into licensing agreement with Ionis.
The Basel-based pharmaceutical group Novartis enters into licensing agreement with Ionis. (generic image)

Ionis developed two therapies that have the potential to significantly reduce cardiovascular risk in patients with underlying lipid disorders. According to a statement, the therapies, which can lower lipidproteins by up to 90 per cent, are currently the subject of clinical studies.

Novartis aims to build a cardiovascular portfolio of targeted therapies to address unmet medical needs of high-risk patients, making Ionis’ two therapies of great interest to the Basel-based pharmaceutical group.

Novartis has therefore entered into an option agreement with Ionis and its affiliate Akcea Therapeutics to develop both treatments. Novartis also has the option to license and commercialise the two treatments following the achievement of specified development milestones. Upon in-licensing, Novartis will be responsible for global development and commercialisation of both treatments.

Read more
Recommend us

Related Content

Premium Partner

Strategic partners

Institutional partner

Official program